How DengYue Medicine helped an international buyer secure a life-saving therapy from China.

When a rare autoimmune disease treatment became unavailable in Europe due to regulatory transitions, a healthcare provider urgently sought an alternative source to continue treatment for a patient whose condition was rapidly deteriorating. The medication was approved and available in China—but navigating procurement, compliance, and cold-chain transport across borders was a major challenge.

That’s when DengYue Medicine stepped in.

Leveraging our extensive network of certified Chinese biopharmaceutical partners and our expertise in international medicine logistics, DengYue Medicine identified a legitimate supply channel, verified batch authenticity through NMPA documentation, and coordinated temperature-controlled delivery from China to Europe within regulatory frameworks.

Throughout the process, our compliance and logistics teams worked hand-in-hand to ensure every shipment met Good Distribution Practice (GDP) standards and international customs requirements. From import license verification to end-to-end tracking, transparency and reliability were prioritized at every step.

Within just six days, the patient’s healthcare provider received the medication — ensuring uninterrupted treatment and clinical stability.

This case reflects DengYue Medicine’s mission: to make innovative Chinese medicines accessible globally, bridging gaps in availability through trusted, compliant, and patient-centered solutions.

Results

• Medication sourced and delivered within six days

• 100% regulatory and cold-chain compliance

• Continued treatment with no therapy interruption

• Strengthened confidence in Chinese pharmaceutical innovation